Case: Genocea Biosciences, Inc.
Court: District of Massachusetts
Class Period: 5/5/2017 - 9/25/2017
Lead Plaintiff Deadline: 1/2/2018
Contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it or This e-mail address is being protected from spambots. You need JavaScript enabled to view it

NEW YORK, NY – November 7, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Genocea Biosciences, Inc. (“Genocea” or the “Company”) (NASDAQ: GNCA).  Genocea is a biopharmaceutical company developing vaccines and immunotherapies.  

Class action litigation has been filed in the United States District Court for the District of Massachusetts against Genocea and certain Company executives on behalf of investors who purchased or otherwise acquired Genocea securities between May 5, 2017 and September 25, 2017, inclusive (the “Class”), alleging violations of the Securities Exchange Act of 1934.

On September 25, 2017 after the market closed, Genocea disclosed that it was halting spending and activities on GEN-003, its lead product candidate, and exploring strategic alternatives for the drug.  The Company also announced that it was cutting 40% of its workforce.

On September 26, 2017, the first trading day following the news, Genocea’s share price fell $4.08 per share, or 76.5%, to close at $1.25 per share on September 26, 2017.

The complaint alleges that throughout the Class Period, the defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies.  Further, the complaint alleges that defendants made false and/or misleading statements and/or failed to disclose that (i) the Company’s finances were insufficient to support Phase 3 trials of GEN-003, (ii) accordingly, Genocea had overstated the prospects for GEN-003, and (iii) as a result of the foregoing, Genocea’s public statements were materially false and misleading at all relevant times.

If you are a member of the proposed Class, you may move the court no later than January 2, 2018 to serve as a lead plaintiff for the purported class.  You need not seek to become a lead plaintiff in order to share in any possible recovery.  If you would like to discuss the complaint or our investigation, please contact us by emailing This e-mail address is being protected from spambots. You need JavaScript enabled to view it or by calling 800-290-1952.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kaplan Fox & Kilsheimer LLP, with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey, has many years of experience in prosecuting investor class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.  If you have any questions about this Notice, the action, your rights, or your interests, please contact: 

Donald R. Hall
KAPLAN FOX & KILSHEIMER LLP
850 Third Avenue, 14th Floor
New York, New York 10022
(800) 290-1952
(212) 687-1980
Fax: (212) 687-7714
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
350 Sansome Street, Suite 400 
San Francisco, California  94104
(415) 772-4700
Fax:  (415) 772-4707
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it